Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT05930834

Exercise Training and Insulin Sensitivity

Exercise Training and Adipose Tissue Insulin Sensitivity

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Missouri-Columbia · Academic / Other
Sex
All
Age
21 Years – 45 Years
Healthy volunteers
Accepted

Summary

Regular exercise participation is known to reduce cardiometabolic disease risk but the impact that exercise training has on adipose tissue (AT) metabolism is poorly understood, particularly in humans. It is well established that exercise training improves whole-body glucose levels and increases insulin sensitivity, and this can occur within one or two weeks. These effects are usually due to adaptations in skeletal muscle, the tissue responsible for the majority of glucose disposal. However, many studies have now determined that exercise training also results in adaptations in AT that improve whole-body metabolic health by improving glucose uptake into the AT. Skeletal muscle is thought to account for approximately 75-85% of glucose uptake , and this process is impaired in .individuals who are insulin-resistant state. It is postulated that the increased level of adiposity that accompanies severe obesity would result in higher dependency on AT for glucose uptake as the AT would be a bigger "sink". Thus the role of AT in inducing whole body insulin resistance is still unclear, particularly in individuals with obesity. This study will examine the changes in AT glucose uptake before and after 4 weeks of exercise training in obese individuals and establish if there are sex differences.

Conditions

Interventions

TypeNameDescription
BEHAVIORALexerciseAll subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max

Timeline

Start date
2024-07-01
Primary completion
2025-10-01
Completion
2025-12-01
First posted
2023-07-05
Last updated
2024-10-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05930834. Inclusion in this directory is not an endorsement.